

CARDINAL HEALTH INC  
Form FWP  
June 17, 2015

**Filed Pursuant to Rule 433 under the Securities Act of 1933**

**Registration Statement No. 333-190741**

**Issuer Free Writing Prospectus dated June 16, 2015**

Cardinal Health, Inc.

Pricing Term Sheet

Issuer: Cardinal Health, Inc.  
Trade Date: June 16, 2015  
Settlement Date: T+5; June 23, 2015  
Underwriters: *Joint Book-Running Managers:*

Goldman, Sachs & Co.

Barclays Capital Inc.

Merrill Lynch, Pierce, Fenner & Smith

Incorporated

Mitsubishi UFJ Securities (USA), Inc.

*Co-Managers:*

Credit Agricole Securities (USA) Inc.

HSBC Securities (USA) Inc.

Standard Chartered Bank

Wells Fargo Securities, LLC

1.950% Notes due 2018

Edgar Filing: CARDINAL HEALTH INC - Form FWP

Aggregate Principal Amount:	\$550,000,000
Maturity Date:	June 15, 2018
Interest Rate:	1.950%
Issue Price:	99.922% of principal amount
Net Proceeds to Issuer (after Underwriting Discount but before expenses):	\$547,096,000
Benchmark Treasury:	UST 1.125% due June 15, 2018
Benchmark Treasury Price:	100- 04+
Benchmark Treasury Yield:	1.077%
Spread to Benchmark Treasury:	90 basis points
Yield to Maturity:	1.977%
Interest Payment Dates:	Semi-annually on June 15 and December 15, commencing December 15, 2015

Make-whole Call: The notes will be redeemable in whole at any time or, in part from time to time, at the Issuer's option, at a redemption price equal to the greater of:

(1) 100% of the principal amount of the notes to be redeemed, or

(2) as determined by a quotation agent, the sum of the present values of the remaining scheduled payments of principal and interest thereon (exclusive of interest accrued to the date of redemption) discounted to the date of redemption on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the adjusted treasury rate plus 15 basis points, plus, in each case, accrued and unpaid interest, if any, on the amount being redeemed to, but excluding, the date of redemption.

Special Mandatory Redemption: If the Principal Closing of Issuer's acquisition of Cordis (the Cordis Acquisition) does not occur on or prior to March 31, 2016, or the Stock and Asset Purchase Agreement for the Cordis Acquisition (the Cordis Purchase Agreement) is terminated, the Issuer will be required to redeem all of the outstanding notes on a special mandatory redemption date at a redemption price equal to 101% of the aggregate principal amount of the notes, plus accrued and unpaid interest, if any, to, but excluding, the special redemption date.

The term *special redemption date* means the earlier to occur of (1) May 30, 2016, if the Principal Closing of the Cordis Acquisition has not occurred on or prior to March 31, 2016, or (2) the 60th day (or if such day is not a business day, the first business day thereafter) following the termination of the Cordis Purchase Agreement for any reason.

CUSIP/ISIN: 14149Y BC1 / US14149YBC12  
3.750% Notes due 2025

Aggregate Principal Amount: \$500,000,000  
 Maturity Date: September 15, 2025  
 Interest Rate: 3.750%  
 Issue Price: 99.928% of principal amount  
 Net Proceeds to Issuer (after Underwriting Discount but before expenses): \$496,390,000

Edgar Filing: CARDINAL HEALTH INC - Form FWP

Benchmark Treasury:	UST 2.125% due May 15, 2025
Benchmark Treasury Price:	98-12
Benchmark Treasury Yield:	2.309%

Spread to Benchmark Treasury:	145 basis points
Yield to Maturity:	3.759%
Interest Payment Dates:	Semi-annually on March 15 and September 15, commencing September 15, 2015
Make-whole Call:	The notes will be redeemable, prior to June 15, 2025 (three months prior to their maturity), in whole at any time or, in part from time to time, at the Issuer's option, at a redemption price equal to the greater of:

(1) 100% of the principal amount of the notes to be redeemed, or

(2) as determined by a quotation agent, the sum of the present values of the remaining scheduled payments of principal and interest thereon that would be due if the notes of such series matured on June 15, 2025, (exclusive of interest accrued to the date of redemption) discounted to the date of redemption on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the adjusted treasury rate plus 25 basis points, plus, in each case, accrued and unpaid interest, if any, on the amount being redeemed to, but excluding, the date of redemption.

The Issuer may also redeem some or all of the notes on or after June 15, 2025 (three months prior to their maturity), at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

CUSIP/ISIN: 14149Y BE7 / US14149YBE77  
4.900% Notes due 2045

Aggregate Principal Amount:	\$450,000,000
Maturity Date:	September 15, 2045
Interest Rate:	4.900%
Issue Price:	99.898% of principal amount
Net Proceeds to Issuer (after Underwriting Discount but before expenses):	\$445,603,500
Benchmark Treasury:	UST 2.500% due February 15, 2045
Benchmark Treasury Price:	89-06

Benchmark Treasury Yield:	3.057%
Spread to Benchmark Treasury:	185 basis points

Yield to Maturity: 4.907%

Interest Payment Dates: Semi-annually on March 15 and September 15, commencing September 15, 2015

Make-whole Call: The notes will be redeemable, prior to March 15, 2045 (six months prior to their maturity), in whole at any time or, in part from time to time, at the Issuer's option, at a redemption price equal to the greater of:

(1) 100% of the principal amount of the notes to be redeemed, or

(2) as determined by a quotation agent, the sum of the present values of the remaining scheduled payments of principal and interest thereon that would be due if the notes of such series matured on March 15, 2045 (exclusive of interest accrued to the date of redemption) discounted to the date of redemption on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the adjusted treasury rate plus 30 basis points, plus, in each case, accrued and unpaid interest, if any, on the amount being redeemed to, but excluding, the date of redemption.

The Issuer may also redeem some or all of the notes on or after March 15, 2045 (six months prior to their maturity), at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

Special Mandatory Redemption: If the Principal Closing of Issuer's acquisition of Cordis (the Cordis Acquisition) does not occur on or prior to March 31, 2016, or the Stock and Asset Purchase Agreement for the Cordis Acquisition (the Cordis Purchase Agreement) is terminated, the Issuer will be required to redeem all of the outstanding notes on a special mandatory redemption date at a redemption price equal to 101% of the aggregate principal amount of the notes, plus accrued and unpaid interest, if any, to, but excluding, the special redemption date.

The term *special redemption date* means the earlier to occur of (1) May 30, 2016, if the Principal Closing of the Cordis Acquisition has not occurred on or prior to March 31, 2016, or (2) the 60th day (or if such day is not a business day, the first business day thereafter) following the termination of the Cordis Purchase Agreement for any reason.

CUSIP/ISIN:

14149Y BD9 / US14149YBD94

**\* We expect that delivery of the notes will be made to investors on or about the 5<sup>th</sup> business day following the date of this prospectus supplement (such settlement being referred to as T+5 ). Under Rule 15c6-1 under the Securities Exchange Act of 1934, trades in the secondary market are required to settle in three business days, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade notes on the date of pricing or the next four succeeding business days will be required, by virtue of the fact that the notes initially settle in T+5, to specify an alternate settlement arrangement at the time of any**



**such trade to prevent a failed settlement. Purchasers of the notes who wish to trade the notes prior to their date of delivery hereunder should consult their advisors.**

**The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at [www.sec.gov](http://www.sec.gov). Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Goldman, Sachs & Co. at 1-201-793-5170, Barclays Capital Inc. at 1-888-603-5847, Merrill Lynch, Pierce, Fenner & Smith Incorporated at t 1-800-294-1322 or emailing [dg.prospectus\\_requests@baml.com](mailto:dg.prospectus_requests@baml.com), and Mitsubishi UFJ Securities (USA), Inc. at 877-649-6848.**